Background: The identification of special types of breast cancer might be of value in assessing prognosis and predicting response to therapy. 
Increasingly, treatment decisions for patients with breast cancer seek to provide interventions, which minimize side-effects without reducing efficacy [1, 2] . Consequently, appropriate identification of prognostic factors and the identification of groups of patients candidate to specific treatment programs continue to represent a major research issue.
Little attention has been dedicated to the identification of special types of breast cancer that display a distinct morphology and might exhibit a distinct prognostic and predictive profile, if compared with invasive ductal carcinomas (IDC) of no special type or not otherwise specified (NOS) [3] . IDC represent approximately 60% to 75% of all breast cancers and constitute a diagnosis of exclusion (i.e. a tumor that does not qualify for a special type), whereas special types of breast cancer account for up to 25% of all breast cancers [4] .
Literature data indicate that the diagnosis of special types of breast cancer might be associated with a different outcome if compared with IDC with similar biological features and stages [3, 5] . In particular, recognition of certain special types of invasive breast carcinoma might allow the identification of women with an extremely good prognosis [5] [6] [7] [8] . However, the use of available information on special types of breast cancer has been limited in tailoring adjuvant therapy, owing to the absence of standardized criteria and suboptimal reproducibility of the histopathologic classification [9] . Furthermore, features that identify for special types of breast carcinomas have not hitherto been studied for correlation with prognosis. Indeed, limited data are available on the biology of a large number of breast cancer subtypes [9] .
In order to provide better information concerning the prognostic significance of special types of primary breast cancer, we analyzed data from a large series of well-characterized patients with breast cancer defined as luminal by the presence of endocrine receptors by immunohistochemistry. We explored patterns of recurrence also according to two immunohistochemically defined tumor subtypes: luminal A and luminal B [10] .
patients and methods
We extracted information from our prospectively collected institutional database on all consecutive breast cancer patients operated at the European Institute of Oncology (EIO) between January 1997 and December 2005. Data on the patient's medical history, concurrent diseases, surgery, pathological evaluation and results of staging procedures including CA 15.3 values were required. Pathological assessment included evaluation of the primary tumor size, histological type and lymph nodes status including a sentinel node biopsy [11] , when applicable. This is a single institution study. All included patients had pathological evaluation carried out at the EIO by the same team of pathologists therefore leading to consistent pathological reporting. Histological types were classified according to World Health Organization criteria and the Armed Forces Institute of Pathology criteria [12, 13] . Tumor grade, peritumoral vascular invasion (PVI), estrogen receptor (ER) and progesterone receptor (PgR) status, Ki-67 labeling index (LI), and human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification were evaluated as previously reported [14] .
In particular, tumor grade was evaluated according to Elston and Ellis [15] . As for the other special tumor types, the included mucinous tumors were pure. In pure mucinous carcinoma, grade was not evaluated considering that these tumors are commonly well differentiated [16] . Immunostaining experiments for the localization of ER and PgR, HER2 protein and Ki-67 antigen were carried out on consecutive tissue sections from the tumor-containing blocks.
The following primary antibodies were used: the monoclonal antibody (MAb) to ER (clone 1D5, at 1/100 dilution; Dako, Glostrup, Denmark), the MAb to PgR (clone 1A6, at 1/800 dilution; Dako), the MIB-1 MAb to the Ki-67 antigen (at 1/1200 dilution; Immunotech, Marseille, France) and the polyclonal antibody (at 1/3200 dilution; Dako) to the HER2 protein.
Only nuclear reactivity, irrespective of its intensity, was taken into account for ER, PgR and Ki-67 antigen, whereas only an intense and complete membrane staining in >10% of the tumor cells qualified for HER2 overexpression (3+). The FISH assay for HER2 was carried out according to the manufacturer's instructions. A HER2 : Cep17 ratio >2.0 was regarded as amplified tumor.
The results for ER, PgR and Ki-67 LI were recorded as the percentage of immunoreactive cells over up to 2000 neoplastic cells. Steroid hormone receptors status was classified as negative in case of <1% immunoreactive tumor cells.
The original pathology reports, carried out before the study conduction, were used, but all cases were reevaluated independently by two of the pathologists. To ensure intra-and interobserver reliability, 5% of cases were blindly re-assessed by the same pathologist and 10% by a different pathologist. If the evaluation differed, then collegial reassessment at the multiheaded microscope was done in order to obtain agreement; this occurred for 1.2% of tumors.
A subtype classification has been adopted based upon immunohistochemical definition of ERs and PgRs, the detection of overexpression and/or amplification of the HER2 oncogene and Ki-67 LI [2, 10] . A patient's tumor was considered luminal A when either one or both of ER and PgR were present, HER2 was not amplified or overexpressed and Ki-67 value was low (<14% of the cells). The tumor was classified as luminal B when ER and/or PgR were present and either Ki-67 value was high, HER2 was amplified or overexpressed or both [1, 17] .
The study was approved by the institutional ethical committee.
statistical analysis
The Fisher's exact test and the Mantel-Haenszel chi-square test for trend were used to assess the association between, categorical and ordinal variables, respectively. The primary end point was disease-free survival (DFS). The secondary endpoints were overall survival (OS) and distant metastasis-free survival (DMFS 
treatment received
All patients received breast conserving surgery or total mastectomy, plus axillary sentinel lymph node biopsy or complete axillary dissection [11] . Systemic adjuvant therapy was recommended according to the prevalent St Gallen treatment guidelines [1, 2, 18, 19] . Adjuvant endocrine therapy in premenopausal patients included the combination of tamoxifen for 5 years plus an luteinizing hormone releasing hormone analog for a minimum of 2 years or tamoxifen alone for 5 years [2] . In postmenopausal patients, an aromatase inhibitor commonly formed part of endocrine therapy either as initial endocrine therapy or after 2-3 years of tamoxifen [1, 2] . Selected postmenopausal patients at low risk or with comorbidities received tamoxifen alone. In patients at higher risk and/or with features of uncertain endocrine responsiveness [1, 2] , chemotherapy was added. Anthracycline-containing chemotherapy was considered as the first option in patients with higher risk [i.e. doxorubicin and cyclophoshamide (AC), for four courses] [20] ; in case of comorbidities or patients' preferences, classical CMF (oral cyclophosphamide, methotrexate and fluorouracil) for three to six courses was considered [21] .
results
All consecutive women operated for breast cancer at the EIO were referred for interdisciplinary evaluation and their data were included in an institutional database. The current study was limited to 8801 women with first primary nonmetastatic breast cancer treated between January 1997 and December 2005, who did not received neoadjuvant chemotherapy and for whom characterization of luminal subtype was possible (i.e. with evaluation of ER, PgR, Ki67 and HER2). Of these, 7372 had breast cancer of the luminal (endocrine-responsive) type and were selected for the present study. The overall distribution of luminal tumors according to histology is shown in Table 1 . A total of 5707 patients (76.2%) were classified as having IDC NOS, 851 (11.4%) lobular (ILC), 338 (4.5%) mixed ductal and lobular, 250 (3.3%) pure cribriform, 143 (1.9%) pure mucinous and 83 (1.1%) pure tubular carcinomas. The remaining histological subtypes papillary (n = 35), tubulo-lobular (n = 30), apocrine (n = 22), micropapillary (n = 19), metaplastic (n = 3), medullary (n = 2), adenoid-cystic (n = 1) or other (n = 3) were less common and therefore not considered for the present analysis. The median follow-up was 5.8 years (maximum: 13 years).
IDC tumors were more frequently of higher grade (26.9%) than other histological subtypes (ILC 10.0%, mixed 14.9%, Table 2 .
treatment Local and regional treatments carried out are shown in Table 1 and systemic adjuvant therapy in Table 3 . A total of 6043 (82.0%) patients underwent conservative surgery and 5299 (71.9%) had sentinel node biopsy. The majority of the patients (4683, 63.5%) received adjuvant endocrine therapy alone (Table 3) . Only 396 patients with luminal A carcinoma (15.3%) were considered to require chemotherapy. Proposed medical treatments varied significantly according to subtypes ( Figure 2) . DFS according to histological grades, separately for each histological type, was reported in the online-only supplementary data (supplemental Figure S1 , available at Annals of Oncology online). Table 4 ).
Conversely, DFS was worse for patients with ILC both overall (HR = 1.27; 95% CI 1.05-1.53; P = 0.01) and within the subgroup of luminal B carcinomas (HR = 1.26; 95% CI 1.01-1.58; P = 0.04). Patients with ILC also had a significant poorer OS (HR = 1.34; 95% CI 1.03-1.74; P = 0.01). Worse DMFS was reported for patients with ILC, among all patients (HR = 1.48; 95% CI 1.16-1.88; P = 0.002), among the subgroup with luminal B carcinomas (HR = 1.46; 95% CI 1.11-1.92; P = 0.007) and among the subgroup with grade 1 carcinomas (HR = 2.83; 95% CI 1.16-6.91; P = 0.02).
A marginal trend to poorer DFS was observed for patients with mixed tumors overall (HR = 1.27; 95% CI 0.98-1.63; P = 0.07), while the poorer DFS was statistically significant for mixed tumors when the analysis was restricted to luminal A carcinomas (HR = 1.77; 95% CI 1.05-3.01; P = 0.03).
Although a similar DFS for mucinous carcinomas and IDC was observed, mucinous carcinomas presented a significantly worse OS when compared with IDC in the subgroup of patients with luminal A carcinomas (HR = 2.96; 95% CI 1.26-6.95; P = 0.01).
The risk estimates for all covariables present in the model are included in the online-only supplementary data (supplemental Table S1 , available at Annals of Oncology online). In particular, in the multivariate analysis luminal B subtype, size of the tumor >2 cm, the presence of positive lymph nodes and Ki-67 ‡ 20% of the cells were significantly associated with poorer DFS, poorer OS and increased risk of distant metastasis. The presence of PVI was significantly correlated with poorer DFS and DMFS.
discussion
Tumor type is commonly not accounted for in the decision about adjuvant therapy. In fact, available data to guide such use are limited. Previous studies have often lacked prolonged follow-up, detailed description of adjuvant systemic treatment received and adequate sample size [22] [23] [24] . The present study, based on a high accrual over a short period ensuring similar clinical management and consistent pathological reporting, provides a large population of patients to examine this subject. By contrast, past series were often collected in a period when today's systemic treatments and modern prognostic and predictive factors were not available. Subtypes of breast cancer were recently identified based on gene expression arrays [25] and a simplified clinicopathologic classification [10] allows ready identification of these subtypes.
Our study is unique in evaluating the outcome of special types of breast cancer within the subgroups with a luminal phenotype. We demonstrated a statistically significant superior DFS for patients with cribriform tumors as compared with IDC. This was also true within patients with grade 1 tumors. Other small series have reported a good prognosis for cribriform carcinoma irrespective of lymph node metastases [26] [27] [28] . However, some studies focusing on cribriform carcinoma have included also mixed variant tumors, a factor which might compromise the outcome since purity of cribriform pattern is important to prognosis [3] .
Cribriform carcinomas have similar immunophenotypes to other low-grade carcinomas [29] and are characterized by types and patterns of genetic aberrations commonly found in most low-grade luminal-type breast carcinomas [30] . However, the better prognosis observed in cribriform tumors in our study supports the hypothesis that they might represent a distinct clinical entity requiring a tailored approach.
Tubular carcinoma also carries an excellent prognosis, irrespective of lymph node metastases [31] [32] [33] [34] [35] [36] . A previous study found that when compared with 'grade 1' IDC, tubular carcinoma had a longer DFS and breast cancer-specific survival [6] . An up-regulation of 'Estrogen Receptor Signaling Pathway' and a less robust activation of the PI3K signaling pathways has been suggested as explaining the favorable prognosis of these tumors if compared with grade 1 IDC [37] . In the present study, patients with tubular carcinoma had a reduced HR for relapse (HR = 0.36) when compared with IDC, although with the limited numbers of events, the difference was not statistically significant. Tubular carcinoma isquite similar to cribriform carcinoma both histologically and biologically. In particular, tubular and cribriform carcinomas have markedly similar genomic features by comparative genomic hybridization [30] . We therefore carried out a pooled analysis of cribriform and tubular carcinomas, which showed a significantly prolonged DFS both among all patients and those with well-differentiated (grade 1) carcinomas.
The clinical relevance of these findings lies in the risk that special types with favorable outcome such as tubular and cribriform carcinoma may be overtreated. This has been avoided in our institution, in that 90% of these patients in the present series received endocrine therapy alone or no adjuvant therapy (Table 3) . The excellent outcome despite the infrequent use of chemotherapy indicates that women with favorable special types of breast cancer may not need chemotherapy.
Mucinous carcinoma is another uncommon special type of breast cancer, accounting for up to 2% of all breast cancers [3, 38] . It has been reported to be associated with a good clinical outcome [39] , perhaps due to down-regulation of gene networks of invasion and proliferation [38] . Although the pure mucinous subtype has been associated with a better prognosis than IDC in a recently published large retrospective analysis [40] , long-term survival has been reported to be similar to IDC by other authors, noting a worsening of prognosis after longer follow-up, as in the present study [41, 42] . These results suggest that patients with mucinous carcinoma should be treated similarly to those with IDC, with systemic adjuvant therapy chosen according to tumor biology, disease extent and patient preference [2] .
ILC, on the other hand, had significantly worse 5-year DFS and OS when compared with luminal IDC in our study. ILC (classic, alveolar, solid, plemorphic, tubulo-lobular) is the most common 'special type' of breast cancer. Conflicting literature data are available on the outcome of ILC, with some studies reporting a worse outcome [43] [44] [45] [46] and others a prognosis similar to IDC [47] [48] [49] [50] . The relative outcome of ILC and IDC was reported to be time dependent. In a study from the International Breast Cancer study Group (IBCSG), 9374 patients were categorized as either pure IDC or ILC [46] . There was a significant early advantage in DFS and OS for the ILC cohort followed by a significant late advantage for the IDC cohort after 6 and 10 years, respectively.
In our study, the finding that ILC was significantly associated with poorer DFS when compared with IDC was observed in a population subjected to an adjuvant therapy program, which might have interfered with the outcome. In the present analysis, patients with ILC were at larger chance of being candidate to endocrine therapy alone and were less likely to receive chemotherapy if compared with IDC.
The poor outcome observed for luminal ILC and the limited response to standard primary chemotherapy previously reported [44, 51] indicate that such patients may require 'tailored' systemic adjuvant therapy programs. These patients should probably be approached through trials based upon proper adjuvant endocrine therapy administered for a prolonged period of time as well as new combinations of cytotoxic agents and molecularly targeted treatments.
The clinical significance of mixed tumors with the presence of both ductal and lobular components has rarely been investigated [52, 53] . The study of mixed tumors is complicated by the fact that the outcome of patients might be determined by the predominant histological type and by the poorer prognostic features of either component type. Thus, in the present study, the outcome for patients with mixed tumors was similar to that for ILC, indicating a similar therapeutic approach.
In conclusion, the results of the present study indicate that an accurate and reliable histopathologic assessment is crucial in order to detect special types of cancer with particular regard to the need for adjuvant systemic treatment. Within the context of special types, tailored treatment investigations and examination of patterns of treatment response during the course of follow*up within subpopulations in multiple randomized trials are required. Such tailored research will require international cooperation to solidify consensus on how to treat individual patients with special types of breast cancer.
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